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ABSTRACT
Objectives To estimate the prevalence of oral
detectable human papillomavirus (HPV) DNA in HIV-
negative men who have sex with men (MSM) attending
a sexual health clinic in London and concordance with
anogenital HPV infection. Such data are important to
improve our understanding of the epidemiology of oral
HPV and the potential use of vaccines to prevent
oropharyngeal cancers.
Methods Paired oral rinse samples and anogenital
samples were available from 151 HIV-negative MSM
within a larger cross-sectional survey. All samples were
tested in parallel for 21 types of HPV DNA using an in-
house assay.
Results The median age of participants was 30 (IQR
25–35). The prevalence of any oral HPV and of high-risk
HPV (HR-HPV) was 13.7% (n=21; 95% CI 8.7 to 20.2)
and 5.9% (n=9; 95% CI 2.7 to 10.9) compared with
64.9% (n=98; 95% CI 56.7 to 72.5) and 34.4%
(n=52; 95% CI 26.9 to 42.6) in any anogenital sample,
respectively. The prevalence of types prevented by the
bivalent (HPV16/18), quadrivalent (HPV6/11/16/18) and
nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccines
was 1.3% (95% CI 0.2 to 4.7), 2.6% (95% CI 0.7 to
6.6) and 4.6% (95% CI 1.9 to 9.3), respectively. There
was no concordance between HPV genotypes detected
in oral and anogenital sites.
Conclusions HR-HPV DNA, including HPV 16/18, was
detected in oral specimens from HIV-negative MSM
attending sexual health clinics, suggesting a potential
role for vaccination, but is far less common than
anogenital infection. How this relates to the risk and
natural history of HPV-related head and neck cancers
warrants further study. Lack of concordance with
anogenital infection also suggests that oral HPV infection
should be considered separately when estimating
potential vaccine impact.
INTRODUCTION
Human papillomavirus (HPV) infection is asso-
ciated with cancers at a number of sites in the head
and neck, most importantly oropharyngeal cancer,
which has been rising in incidence in recent
decades.
1 The global estimate of oral HPV preva-
lence in men was 5%
2 and estimates in men who
have sex with men (MSM) outside the UK range
from 3% to 57%,
34yet few studies have compared
oral HPV prevalence in heterosexual and MSM
populations.
3 Furthermore, the natural history of
oral HPV infection and its role in the development
of head and neck cancers is not well understood.
5
HPV infection and related disease in MSM is of
particular interest, given the potential for preven-
tion by vaccination.
6
Estimating the potential beneﬁt of vaccinating
MSM requires knowledge of the epidemiology of
oral HPV infection. To date, only three studies
involving a total of 877 HIV-negative MSM have
been conducted to estimate oral high-risk HPV
(HR-HPV) prevalence, and results are not consist-
ent (2%,
7 9%,
4 17%
8). Likewise, the relationship
between oral and anogenital HPV infection in
MSM is not well understood.
Most transmission models of HPV infection used
to inform vaccine programme design assume that
infection occurs through anogenital contact, ignor-
ing the role of oral–anogenital contact. Indeed, esti-
mates of concordance between oral and anogenital
HPV infection not only have implications for
vaccine assessment but also for understanding the
key epidemic characteristics such as route of acqui-
sition, whether anogenital infections are acquired
simultaneously or via separate risk acts/partner-
ships, or whether men transfer infections from one
anatomical site to another (auto-inoculation).
We describe age-speciﬁc oral HPV prevalence
and the concordance between detection of type-
speciﬁc HPV DNA in oral and anogenital speci-
mens from HIV-negative MSM attending a sexual
health clinic in central London.
METHODS
Study methods, including sample size calculations,
have been reported elsewhere.
9 In brief, from
October 2010 to July 2012, a cross-sectional study
was conducted to examine the risk factors and
prevalence of HPV DNA in MSM attending the
sexual health clinic at the Mortimer Market Centre
(MMC), London. Consecutive men aged 16–
40 years, who reported anal or oral sex with
another man in the last 5 years, were invited to par-
ticipate. Participants provided written informed
consent, completed a computer-assisted self-
interview questionnaire and anogenital specimens
(ﬁrst-void urine, intra-anal swab and external
genital swab (glans penis/coronal sulcus/penile shaft/
scrotum/perianal area)) were collected by the study
nurse using a standardised protocol.
Participants who enrolled in the ﬁnal ﬁve months
of the study were also invited to provide an oral
specimen involving a 30 s gargle/rinse with 15 mL
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3 Oral
samples were refrigerated immediately and processed the same
day. To process, the rinse was centrifuged at 3200 rpm for
15 min at 4°C and, after the supernatant was discarded, the
pellet was resuspended in 20 mL of cold phosphate buffered
saline (PBS) (4°C). The centrifugation/resuspension was repeated
twice and the ﬁnal pellet was resuspended in 1.2 mL of PBS
with repeat pipetting and vortexing to ensure a homogeneous
sample. Samples were stored at −20°C until shipment to the
laboratory on dry ice at the end of the study. Specimens were
removed for batch processing wherein all available specimens
from each individual were processed for DNA extraction and
HPV testing in the same run. Nucleic acid extraction and PCR
ampliﬁcation, HPV genotyping and determination of specimen
integrity methods have been previously described.
10 HPV geno-
types 16/18/31/33/35/39/45/51/52/56/58/59/68 were considered
HR-HPV types.
Here we report HPV prevalence and demographic and behav-
ioural characteristics among participating MSM with both oral
and anogenital specimens that were adequate for PCR-based HPV
detection, for bivalent (HPV16/18), quadrivalent (HPV6/11/16/
18) and nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccine-
preventable types together and individually, and for selected other
HPV types: 35/39/51/56/59/68/26/53/66/70/73/82. CIs (95%)
around prevalence estimates were determined by the Clopper–
Pearson (exact) method.
RESULTS
There were 522 participants in the full study (n=522) and 177
gave an oral specimen. Participant and specimen numbers are
shown in online supplementary ﬁgure S1. The study population
was slightly younger than MSM attending MMC during the
recruitment period (data not shown) and were more likely to be
a new patient at the clinic than those who declined to partici-
pate; 163/173 (94%) HIV-negative MSM provided oral speci-
mens, 153/173 (88%) were adequate for HPV testing and 151/
173 (87%) had at least one matching anogenital specimen (ie,
urine, anal swab or external genital swab). Also, 127/151 (84%)
had an anal swab, 135/151 (89%) had an external genital swab
and 143 (95%) had a urine specimen.
Online supplementary table S1 displays characteristics of sub-
study participants. The median age of respondents with
adequate paired specimens was 30 (IQR 25–35), 75% were of
white ethnicity and 64% had >30 lifetime sexual partners.
Nine MSM had HR-HPV DNA detected in their oral speci-
mens, and three had LR-HPV . Table 1 shows the oral prevalence
of any HPV was 14% (95% CI 9% to 21%), HR-HPV was 6%
(95% CI 3% to 11%) and of HPV16 was 0.7% (95% CI 0% to
4%). Prevalence estimates of bivalent, quadrivalent and nonava-
lent vaccine-preventable types were 1%, 3% and 5%, respect-
ively. By comparison, the anogenital prevalence of any HPV was
65% (n=98; 95% CI 57 to 73) and HR-HPV was 34% (n=52;
95% CI 27 to 43). None of the 151 pairs had the same HPV
type detected in both oral and anogenital samples; 14 (9%)
pairs had any HPV detected in both oral and anogenital sites
(see online supplementary table S2).
DISCUSSION
Our observed prevalence of oral HR-HPV of 6% was higher
than that of the global estimate in healthy men and women
(3.5%; 95% CI 3.0% to 4.1%) yet the CIs overlap.
2 Our results
lie within the range of estimates for HIV-negative MSM.
478
Although MSM are at high risk of anogenital HPV-related
disease, none of the men with an oral HPV infection had the
same genotype of HPV infection at any anogenital site. The
prevalence of any HPV type was also higher in anogenital than
oral samples.
Differences in estimates of oral prevalence between studies
could be due to both technical and population differences.
Methods of oral specimen collection, processing, storage, DNA
extraction and test sensitivity and speciﬁcity differ across
studies. We followed the oral rinse collection protocol from the
Human Papillomavirus Infection in Men (HIM) study that is
thought to yield more HPV DNA from the entire oral cavity
than oral swabs and used a similar processing method.
w1
In the longitudinal Multicenter AIDS Cohort (MAC) study,
HPV , particularly HR-HPV , in MSM was more likely to persist
at the anus than the oral cavity, while heterosexual men were as
likely to have persistent oral HPV as MSM, but less likely to
have persistent anal HPV .
8 In the HIM study in which only
3.5% were MSM, HPV persistence was similar at oral and ano-
genital sites but the incidence was lower in the oral cavity com-
pared with anogenital sites.
w2 In a cross-sectional assessment,
persistent infections cannot be differentiated from those that are
transient, and we did not measure oral cavity symptoms, but
our lower oral prevalence as compared to anogenital prevalence
may be due to both a lower incidence at oral sites and a lower
proportion of persistent infections. While we have grouped
HR-HPV types, deﬁned by their oncogenic potential at the
Table 1 Human papillomavirus (HPV) DNA prevalence in oral
cavity of men who have sex with men
N=151
n Per cent 95% CI
Any HPV type* 21 13.9 8.8 to 20.5
Multiple types (two or more) 1 0.7 0.0 to 3.6
Multiple HR types† (two or more) 0 0.0 0.0 to 2.4
Any bivalent vaccine types‡ 2 1.3 0.2 to 4.7
Any quadrivalent vaccine types‡ 4 2.6 0.7 to 6.6
Any nonavalent vaccine types‡ 7 4.6 1.9 to 9.3
Possible high-risk types§ 0 0.0 0.0 to 2.4
High-risk HPV types (HR-HPV)† 9 6.0 2.8 to 11.0
HPV16 1 0.7 0.0 to 3.6
HPV18 1 0.7 0.0 to 3.6
HPV31 0 0.0 0.0 to 2.4
HPV33 1 0.7 0.0 to 3.6
HPV35 0 0.0 0.0 to 2.4
HPV39 0 0.0 0.0 to 2.4
HPV45 1 0.7 0.0 to 3.6
HPV51 1 0.7 0.0 to 3.6
HPV52 1 0.7 0.0 to 3.6
HPV56 3 2.0 0.4 to 5.7
HPV58 0 0.0 0.0 to 2.4
HPV59 0 0.0 0.0 to 2.4
HPV68 0 0.0 0.0 to 2.4
Low-risk HPV types
6 and/or 11¶ 3 2.0 0.4 to 5.7
6¶ 3 2.0 0.4 to 5.7
11 0 0.0 0.0 to 2.4
*Sample reacted to the universal probe for HPV DNA.
†HR types 16/18/31/33/35/39/45/51/52/56/58/59/68 classified according to the
International Agency for Research on Cancer monograph carcinogenic or probably
carcinogenic.
‡Vaccine types: HPV16/18 are bivalent, HPV6/11/16/18 are quadrivalent and HPV6/
11/16/18/31/33/45/52/58 are nonavalent.
§Possible high-risk types: 26/53/66/70/73/82.
¶One with co-infection with HPV18.
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w3
Our ﬁnding of a lack of concordance between oral and ano-
genital specimens is similar to those in HIV-positive men
reported by Videla et al (predominantly MSM)
w4 and Parisi
et al.
w5 However, Edelstein et al found that 15/17 men (predom-
inantly heterosexual) had the same type detected at oral and ano-
genital sites.
w6 Lower prevalence in the oral cavity and the lack
of concordance with anogenital infection suggest that oral HPV
infections are acquired independently of anogenital infections, or
that they are less likely to reactivate from latency than anogenital
infections, and would also suggest that auto-inoculation does not
commonly occur. Differences in sensitivity of the detection
methods may also have contributed to some disparity in HPV
detection between anatomical sites but is unlikely to account for
the magnitude of the difference observed.
We have previously demonstrated that our study population is
at greater risk of STI acquisition than MSM attending other
SHCs in England and MSM who attend SHCs in the general
population of Britain.
9 If oral HPV infection is a function of
partner change, the estimates of oral HPV prevalence in our
MSM population may be inﬂated compared with MSM attend-
ing SHCs more generally in Britain.
The sample size of this substudy was too small to accurately
estimate oral–anogenital concordance (if true population preva-
lence is below 6%) but could estimate oral prevalence within
5% if the true population prevalence was 13%.
HPV vaccines can prevent oral HPV infections,
w7 but whether
they are effective against HPV-related head and neck cancers has
yet to be shown. The lack of concordance between oral and ano-
genital specimens suggests that the additional potential beneﬁto f
HPV vaccination for preventing oral HPV-related disease should
be considered in epidemiological and natural history models, in
addition to anogenital HPV infection. Further studies, including
meta-analyses, are needed to elucidate the epidemiology and
natural history of oral HPV infection.
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